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Recently, N-(4-18F-fluorobenzoyl)-interleukin-2 (18F-FB-IL2) was introduced as PET tracer for 
T-cell imaging. However, production is complex and time-consuming. Therefore, we developed 
two radiolabeled interleukin-2 (IL-2) variants, namely aluminum 18F-fluoride-(restrained 
complexing agent)-IL-2 (18F-AlF-RESCA-IL2) and 68Ga-gallium-(1,4,7-triazacyclononane-4,7-
diacetic acid-1-glutaric acid)-IL-2 (68Ga-Ga-NODAGA-IL2) and compared their in-vitro and in-
vivo characteristics with 18F-FB-IL2. Methods: Radiolabeling of 18F-AlF-RESCA-IL2 and 68Ga-
Ga-NODAGA-IL2 was optimized and stability was evaluated in human serum. Receptor binding 
was studied with activated human peripheral blood mononuclear cells (hPBMCs). Ex-vivo tracer 
biodistribution in immunocompetent BALB/cOlaHsd (BALB/c) mice was performed at 15, 60 
and 90 min after tracer injection. In-vivo binding characteristics were studied in severe combined 
immune-deficient (SCID) mice inoculated with activated hPBMCs in Matrigel. Tracer was 
injected 15 min after hPBMCs inoculation and a 60-min dynamic PET scan was acquired, 
followed by ex-vivo biodistribution studies. Specific uptake was determined by co-injection of 
tracer with unlabeled IL2 and by evaluating uptake in a control group inoculated with Matrigel 
only. Results: 68Ga-Ga-NODAGA-IL2 and 18F-AlF-RESCA-IL2 were produced with 
radiochemical purity >95% and radiochemical yield of 13.1±4.7% and 2.4±1.6% within 60 and 
90 min, respectively. Both tracers were stable in serum, with >90% being intact tracer after 1h. 
In-vitro, both tracers displayed preferential binding to activated hPBMCs. Ex-vivo biodistribution 
studies in BALB/c mice showed higher uptake of 18F-AlF-RESCA-IL2 than 18F-FB-IL2 in liver, 
kidney, spleen, bone and bone marrow. 68Ga-Ga-NODAGA-IL2 uptake in liver and kidney was 
higher than 18F-FB-IL2 uptake. In-vivo, all tracers revealed uptake in activated hPBMCs in SCID 
mice. Low uptake was seen after a blocking dose of IL2 or in the Matrigel control group. In 
addition, 18F-AlF-RESCA-IL2 yielded highest contrast PET images of target lymph nodes. 
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Conclusions: Production of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 is simpler and 
faster than 18F-FB-IL2. Both tracers showed good in-vitro and in-vivo characteristics with high 
uptake in lymphoid tissue and hPBMC xenografts.  
 
Keywords: PET imaging, T-cells, immunotherapy, interleukin-2, radiopharmaceuticals 
 
  




Molecular imaging of immune cells for diagnosis and therapy evaluation in inflammatory and 
infectious diseases has been performed for decades (1,2). Now, interest in visualizing the immune 
response in cancer is also growing, as a result of the introduction of cancer immunotherapies. 
Immune checkpoint inhibitors have anti-tumor effects across several tumor types. However, not 
all patients respond and some patients experience serious immune-related side effects. Therefore, 
strategies to select patients and optimize therapy are needed. Molecular imaging of immune cells 
might be a suitable method for patient selection, response prediction and treatment evaluation in 
this context (2).  
 T-cells are major players in both immune-related diseases and the tumor-immune 
response. During an immune response, T-cells secrete the protein interleukin-2 (IL2). IL2 binds 
to the IL2 receptor (IL2-R), consisting of three subunits: IL2-Rα (CD25), IL2-Rβ (CD122) and 
IL2-Rγ (CD132) (3-6). Binding of IL2 to this complex leads to T-cell activation and 
differentiation (3). The IL2-R is not only expressed on activated cytotoxic T-cells, but also on 
other subpopulations, such as regulatory T-cells. Specific binding of radiolabeled IL2 to T-cells 
could be exploited for molecular imaging and might provide insight in immune responses. 
 Recombinant human IL2 binds to human and murine IL2-R and has been radiolabeled 
previously with isotopes for single-photon emission computed tomography (SPECT) like 
technetium-99m (99mTc) and iodine-123 (123I) (7-9). As positron emission tomography (PET) 
offers better resolution compared to SPECT, the fluor-18 (18F) labeled PET tracer N-(4-18F-
fluorobenzoyl)-interleukin-2 (18F-FB-IL2) was developed. 18F-FB-IL2 PET imaging detected 
subcutaneously (s.c.) injected activated T-cells and tumor infiltration of T-cells in response to 
radiotherapy and immunization (10-12). Clinical trials with 18F-FB-IL2 are ongoing. However, 
radiotracer production is complex, requiring 2.5h and several synthesis modules. Moreover, the 
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production yields sufficient radiotracer for only one or two patients (13). Therefore, we aimed to 
develop other radiolabeled IL2 PET tracers. First, we developed a simplified method for 
radiolabeling with 18F, requiring less synthesis steps. Secondly, we used another PET isotope, 
gallium-68 (68Ga), which is a generator-produced radioisotope. Here we present the development 
18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 (Fig. 1). To determine their potential for 
clinical use, in-vitro and in-vivo characteristics were evaluated and compared to 18F-FB-IL2. For 
this purpose, in-vitro binding assays with activated human peripheral blood mononuclear cells 
(hPBMCs) and ex-vivo biodistribution studies in immunocompetent BALB/cOlaHsd (BALB/c) 
mice were performed. In addition, PET imaging and ex-vivo biodistribution studies were 




Production Of 18F-FB-IL2 
The production method of 18F-FB-IL2 has been described previously (10). Adaptations to 
this production method were made to improve tracer yields (13). 
 
Production Of 18F-AlF-RESCA-IL2 
We developed a simplified method to label IL2 with 18F, using the indirect 18F-AlF-
RESCA (REStrained Complexing Agent) methodology, combining chemical advantages of a 
chelator-based radiolabeling method with the unique physical properties of 18F (14-16). 18F-AlF 
was allowed to react with the RESCA-tetrafluorophenol ester ((±)-H3RESCA-TFP) (Leuven 
University, Belgium). Subsequently, the 18F-AlF-RESCA complex was conjugated with IL2. The 
complete synthesis is described in the supplementary methods. 




Production Of 68Ga-Ga-NODAGA-IL2 
 Our second strategy was radiolabeling of IL2 with 68Ga. Due to the short half-life of 
68Ga, less synthesis steps and synthesis time are allowed. First 2,2′-(7-(1-carboxy-4-((2,5-
dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane1,4-diyl)diacetic-acid (NODAGA-NHS) 
was conjugated to IL2, followed by radiolabeling with 68Ga. We used two synthesis methods. In 
method 1, 68Ga was eluted from the PS-H+ cartridge in the cationic form (0.1M hydrochloric 
acid, HCl). However, large amounts of HCl are needed to efficiently elute all 68Ga, leading to low 
concentrations of 68Ga. Thus, for obtaining high concentrations of 68Ga in a non-fractionated 
elution, we implemented method 2, in which 68Ga was eluted from a PS-HCO3 cartridge with 
deionized water (17). The complete synthesis methods are described in the supplementary 
methods.  
 
In-Vitro Binding Assays  
In-vitro binding to IL2-Rs was determined by performing binding assays with hPBMCs, 
isolated from peripheral blood from healthy volunteers by Ficoll-Paque Plus separation (GE 
Healthcare). Cells were kept in RPMI-1640 medium (GIBCO) supplemented with 10% fetal calf 
serum. Isolated hPBMCs were activated by incubation with 5 μg/mL of phytohemagglutinin 
(PHA, Sigma-Aldrich) in a 5% CO2 atmosphere at 37°C for 48h (10). As control, non-activated 
hPBMCs were incubated 48h at 37°C and 5% CO2. On the day of the experiment, another batch 
of hPBMCs were isolated, to compare CD25 (IL2-Rα) expression on these freshly isolated cells 
with expression on 48h incubated cells. 
Approximately 5x105 cells were incubated with 50 µL tracer solution at 37˚C for 30 min. 
Cells were washed twice with 1 mL ice-cold phosphate buffered saline (PBS) containing 1% 
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human serum albumin (HSA, Sanquin). Activity in the cell fraction was measured in a gamma-
counter (Wizard2 2480-0019, SW 2.1, PerkinElmer). Tracer uptake was corrected for the number 
of viable cells, counted manually using trypan blue. Uptake was expressed as percentage of cell-
associated radioactivity per 500,000 cells. For 18F-FB-IL2 and 18F-AlF-RESCA-IL2 four 
independent experiments were performed, each experiment in triplicate, for 68Ga-Ga-NODAGA-
IL2 two independent experiments were performed, each experiment in triplicate.  
 
In-Vitro Stability Studies 
The stability of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 was evaluated by 
adding 50 μL tracer to 200 μL of human serum. The mixture was vortexed and incubated at 37°C 
for 60 and 120 min. After incubation, radiochemical purity was determined by a trichloroacetic 
acid (TCA) precipitation assay (18,19).  
 
Animals Studies  
Animal studies were performed according to Dutch Regulations for Animal Welfare (IvD 
number 16395-01-007). The protocol was approved by the animal ethical committee of the 
University of Groningen. Animals were randomly assigned to different groups. A power 
calculation has been performed to calculate the experimental group size. With an expected 
variation coefficient of 10%, a meaningful effect size of 25%, a confidence interval of 95% and a 
power of 90%, a minimum of 5 animals per group is required. Therefore 5-6 animals were 
included in each group. Exclusion criteria were abnormal behavior, signs of sickness, reduction 
of body weight >15% and death.  
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     Biodistribution Studies And In-Vivo Stability In BALB/c mice. Ex-vivo biodistribution studies 
were performed in 5-8 weeks old, immunocompetent BALB/c mice (Envigo). Weights of animals 
were comparable. Tracer (150 µl) was injected via the penile vein: 4.20±0.8 MBq (0.75±0.22 µg) 
[18F]FB-IL2; 1.21±0.95 MBq (0.25±0.24 µg) 18F-AlF-RESCA-IL2; 0.55±0.13 MBq (0.32±0.18 
µg) 68Ga-Ga-NODAGA-IL2 (method 1). Mice were sacrificed at the following time-points post-
injection (p.i.): 15, 60 and 90 min (n=6 mice per time-point). Organs were dissected and counted 
in a gamma-counter. Bone marrow was isolated from the hind limb long bones (femur and tibiae) 
via centrifugation. Uptake in organs was calculated as percentage of injected dose per gram of 
tissue (%ID/g). Total injected dose was determined by measuring activity in the syringe before 
and after injection. In-vivo stability was determined in plasma samples by a TCA precipitation 
assay. 
 
     PET Imaging And Ex-Vivo Biodistribution In SCID Mice With A hPBMC Xenograft. PET 
studies were performed in 5-8 weeks old Fox Chase severe combined immunodeficient (SCID) 
beige mutant mice (Envigo). Mice were s.c. implanted with 10x106 48h PHA-activated hPBMCs 
in 300 µL 1:1 PBS:Matrigel (Corning) in the right shoulder. As negative control group, mice 
were s.c. inoculated with Matrigel only. Tracer was injected via the penile vein 15 min after 
inoculation: 1.17±0.62 MBq (0.15±0.11 µg) 18F-FB-IL2; 2.10±2.41 MBq (0.18±0.12 µg) 18F-
AlF-RESCA-IL2; 0.44±0.18 MBq (0.26±0.13 µg) 68Ga-Ga-NODAGA-IL2 (method 2). For 
blocking experiments, a third group inoculated with 10x106 PHA activated hPBMCs, received a 
co-injection of tracer with a blocking dose unlabeled IL2 (100 µg). Directly after tracer injection 
a 60-min dynamic PET scan was made using a Focus 220 PET scanner (CTI Siemens), followed 
by a 15 min transmission scan with a 57Co point source to correct for tissue attenuation, random 
coincidences and scatter. After the scan, mice were sacrificed and organs were dissected and 
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counted in a gamma-counter. During all scans and invasive procedures mice were anesthetized 
with isofluorane/medical air inhalation anesthesia (5% induction, 2.5% maintenance). 
 
PET Reconstruction  
PET data was reconstructed into six frames and corrected for radioactive decay, random 
coincidences, scatter, and attenuation. Reconstructed images were analyzed using PMOD 
software (version 3.9, PMOD technologies LCC). Three-dimensional regions of interest (ROI) 
were drawn around the site of cell inoculation. For other organs a fixed-sizes sphere was drawn in 
representative parts of the organs. PET data is presented as %ID/g.  
 
FACS Analysis  
The CD25 (IL2-Rα) expression on hPBMCs was determined by fluorescence-activated 
cell sorting (FACS) analysis. For in vitro experiments hPBMCs were washed once with 3 mL 
ice-cold PBS and resuspended in 500 µL PBS. To select viable cells, 5 µL Zombie Aqua 
(Biolegend) was added and incubated in the dark at room temperature for 15 min. Cells were 
washed with PBS containing 5% fetal calf serum and resuspended in PBS containing 2% fetal 
calf serum (FACS buffer), to a concentration of 1x106 cells/mL. To 0.1 mL cell suspension, either 
5 µL FITC-conjugated mouse anti-human antibody CD25 (ImmunoTools) or mouse FITC-IgG 
(BD Biosciences) as a control was added. Then 5 µL PE-conjugated anti-human CD3 antibody 
(eBioscience) was added and cells were incubated for 45 min on ice. Thereafter cells were 
washed twice with 3 mL cold FACS buffer and resuspended in 0.1 mL FACS buffer. FACS 
measurements were performed on a BD FACSVerse apparatus (BD Biosciences). FACS data 
were analyzed using Flow-Jo software (version 10). Cells were gated for living cells, followed by 
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CD3-positive cells. In this population the percentage of CD25-positive cells was selected. For in-
vivo experiments hPBMC activation was confirmed by FACS analysis of CD25 only. 
 
Statistical Analysis  
Data are presented as mean±standard deviation (SD). Statistical analyses between two 
groups were performed using an unpaired two-tailed t-test (in-vitro binding data and stability 
data) or a Bonferroni corrected Mann-Whitney U-test (PET imaging and biodistribution data) 
(Graphpad Prism 7.0). P-values ≤0.05 were considered statistically significant.  
 
RESULTS  
Production Of 18F-FB-IL2 
18F-FB-IL2 was obtained with a radiochemical yield of 1.0±0.4%, a molar activity of 
342±385 GBq/μmol and a radiochemical purity >95% within 150 min. 
 
Production Of 18F-AlF-RESCA-IL2 
In the first step, the 18F-AlF-RESCA-TFP complex was formed at room temperature with 
high yield (radiochemical yield >80%). The subsequent conjugation of IL2 with 18F-AlF-
RESCA-TFP provided the final product, 18F-AlF-RESCA-IL2, with a radiochemical yield of 
2.4±1.6%, a molar activity of 910±927 GBq/μmol and a radiochemical purity >95% within 90 
min. 
 
Production Of 68Ga-Ga-NODAGA-IL2  
The conversion of NODAGA-IL2 into 68Ga-Ga-NODAGA-IL2 according to method 1 (as 
described in method section) resulted in almost quantitative yields (85±29%) when small 
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volumes (100-200 μL, 20-100 MBq) of freshly eluted 68Ga-Cl3 were used. When large volumes 
of 68Ga-Cl3 (1 mL, 200-600 MBq) were used, the yields dropped to 6.0±6.6%. 
Labeling of NODAGA-IL2 with small volumes (200 μL, 200-600 MBq) of freshly eluted 
68Ga-Cl3 according to method 2 resulted in 68Ga-NODAGA-IL2 with a radiochemical yield of 
13.1±4.7%, a molar activity of 76±34 GBq/μmol and a radiochemical purity >91% within 60 
min. 
 
In-Vitro Binding Assays  
18F-AlF-RESCA-IL2 uptake in activated hPBMCs (73±27.6%) was substantially higher 
than 18F-FB-IL2 (4.8±2.8%, P=0.015) and 68Ga-Ga-NODAGA-IL2 uptake (12.7±0.1%, P=0.019) 
(Fig. 2A). When comparing ratios of activated/non-activated, it was found that the new tracers 
were equally selective as 18F-FB-IL2 (Fig. 2B). All tracers showed a reduction in cell binding in 
fresh and non-activated hPBMCs compared to uptake in activated hPBMCs. In the activated 
hPBMCs, more CD3-positive T-cells (Supplemental Fig. 1) expressed CD25 than in the 
incubated non-activated hPBMCs (32.1±6.0% versus 3.4±2.1%, P=0.002) and freshly isolated 
hPBMCs (3.1±1.2%, P=0.001). 
 
In-Vitro Stability Studies  
18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 showed comparable high stability in 
human serum, with >90% of both tracers remaining intact after 1h and 2h (Fig. 3). For 
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Animals Studies  
     Ex-Vivo Biodistribution Studies In Immunocompetent Mice. Ex-vivo biodistribution studies 
showed high uptake of 18F-FB-IL2 at sites of renal excretion (Fig. 4; Supplemental Table 1). 
After 15 min kidney uptake of 18F-AlF-RESCA-IL2 is higher compared to 18F-FB-IL2 (P=0.009) 
(Supplemental Table 1). However, activity found in urine is higher for 18F-FB-IL2 (P=0.004), 
indicating faster renal excretion. At 60 and 90 min p.i., 18F-AlF-RESCA-IL2 showed higher 
uptake than 18F-FB-IL2 in liver, kidney, spleen, bone and bone marrow. 68Ga-Ga-NODAGA-IL2 
showed a comparable biodistribution pattern to 18F-AlF-RESCA-IL2, with high uptake in liver 
and kidneys. Moreover, 68Ga-Ga-NODAGA-IL2 uptake in the kidneys was higher than both 18F-
FB-IL2 and 18F-AlF-RESCA-IL2 at all time-points (Fig. 4). 18F-AlF-RESCA-IL2 showed highest 
uptake in lymphoid organs, such as spleen, lymph nodes and bone marrow, at 60 min and 90 min. 
In-vivo stability of 18F-AlF-RESCA-IL2 was comparable to 18F-FB-IL2 at 90 min p.i. 
(18F-FB-IL2 81%±9% versus 18F-AlF-RESCA-IL2 72±9% , P=0.058) (Supplemental Fig. 2).  
68Ga-Ga-NODAGA-IL2 was less stable compared to 18F-FB-IL2 at 90 min p.i. (68Ga-Ga-
NODAGA-IL2 65%±5%, P=0.003). 
 
     PET Imaging And Ex-Vivo Biodistribution In SCID Mice With A hPBMC Xenograft. Activated 
hPBMC xenografts inoculated in SCID mice were visualized with all tracers by dynamic PET 
imaging. No uptake was observed in the Matrigel control group or after co-injection of tracer 
with a blocking dose unlabeled IL2. PET images of all tracers showed high uptake in liver and 
kidney, which did not substantially change over time (data not shown).  
With 18F-FB-IL2 PET, lymph nodes could be detected in only three out of five mice (Fig. 
5A), while 18F-AlF-RESCA-IL2 PET could clearly visualize lymph nodes in all mice at 60 min 
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p.i. (Fig. 5B). With 68Ga-Ga-NODOGA-IL2 PET, lymph nodes could be detected as well, 
although not as clear as with 18F-AlF-RESCA-IL2 PET (Fig. 5C).  
The PET results were confirmed by ex-vivo studies with higher uptake in activated 
PBMCs than in Matrigel control for all tracers (Fig. 6, Supplemental Table 2). A blocking dose of 
unlabeled IL2 reduced tracer uptake in PBMCs, with the largest reduction for 18F-AlF-RESCA-
IL2 (18F-FB-IL2=43.2%; 18F-AlF-RESCA-IL2=67.5%; 68Ga-Ga-NODAGA-IL2=26.9%).  
   
DISCUSSION  
We developed two radiolabeled IL2 tracers, namely 18F-AlF-RESCA-IL2 and 68Ga-Ga-
NODAGA-IL2. Both tracers could be produced consistently with a shorter production time 
compared to 18F-FB-IL2. Although labeling of 18F-AlF-RESCA-IL2 gives similar decay-
corrected radiochemical yields as 18F-FB-IL2, practical amounts of 18F-AlF-RESCA-IL2 
produced are 50% higher due to shorter production time. In addition, the production requires only 
one synthesis module. This is an advantage for clinical use, as more production runs could be 
planned and thus, more patients can be scanned. The radiochemical yield of 68Ga-Ga-NODAGA-
IL2 strongly depends on the volume in which 68GaCl3 can be obtained. An advantage of this 
tracer could be that no cyclotron is needed for radioisotope production, which allows production 
at sites without a cyclotron.  
RESCA was chosen as chelator for the incorporation of Al18F, since the complex can be 
formed at room temperature, preventing potential degradation of the IL2 protein at higher 
temperatures. Although RESCA was successfully conjugated to IL2, most of the direct 
radiolabeling attempts did not yield any product, most likely due to the substantial loss of 
RESCA-IL2 conjugate in the tC2 cartridge during purification (data not shown). Therefore, it was 
decided to use an indirect radiolabeling method. This approach provided the desired product, 
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although at low radiochemical yield of 2.4±1.6%. Nevertheless, starting with less than 50 GBq 
allows production of sufficient 18F-AlF-RESCA-IL2 for several patients (1375±791 MBq; 
recommended injected dose 200 MBq).  
For the 68Ga-based IL2 tracer NODAGA was chosen as chelator, because it possesses a 
smaller coordination pocket forming more stable complexes with 68Ga. Moreover, it allows 
labeling with 68Ga at room temperature (20,21). During 68Ga-Ga-NODAGA-IL2 production, 
addition of higher amounts of 68Ga-Cl3 led to yields <10%. A plausible explanation for this is the 
low amounts of protein remaining after conjugation, as most of the conjugated NODAGA-IL2 is 
lost during tC2 purification. With these low radiochemical yields and a maximum amount of 1 
GBq eluted from the 68Ge/68Ga-generator, 68Ga-Ga-NODAGA-IL2 becomes less suitable for 
clinical use, since it would be difficult to reliably obtain a patient dose. Therefore, in order to use 
68Ga-Ga-NODAGA-IL2 in clinical studies, further optimization is warranted. 
Our study showed that 18F-AlF-RESCA-IL2 had highest in-vitro uptake in hPBMCs and 
highest in-vivo uptake in target tissues of BALB/c mice, such as lymph nodes, spleen and bone 
marrow. Since IL2 is injected in a sub-pharmacological dose, no adverse effects are expected. In 
addition, in the first clinical study with 18F-FB-IL2, no adverse effects due to radiation burden 
were observed (data not shown). Therefore, we do not expect additional toxicity from the new 
analogues. In contrast to 18F-FB-IL2 and 68Ga-Ga-NODAGA-IL2, which mainly have a renal 
clearance, 18F-AlF-RESCA-IL2 has higher hepatobiliary clearance. This can be attributed either 
to presence of the RESCA moiety, which introduces an additional charge, or to presence of 
degradation products, such as unconjugated 18F-AlF-RESCA or free 18F-AlF (16,22). These high 
uptake values obtained in excretory organs are in the same range as obtained with previous IL2-
based tracers, where no renal or hepatic toxicity was found (23-25). A limitation for clinical use 
of 68Ga-Ga-NODAGA-IL2 is high retention in kidneys, which can lead to radiation burden due to 
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its higher positron energy compared to 18F-fluorine. Therefore, 18F-AlF-RESCA-IL2 might be 
preferred for clinical molecular imaging studies. PET images obtained from 18F-AlF-RESCA-IL2 
showed less background and therefore, better contrast images, compared to the other tracers. In 
addition, lymph nodes could be visualized with 18F-AlF-RESCA-IL2 in all animals, while with 
18F-FB-IL2 PET lymph nodes were only visible in some animals, indicating good targeting 
characteristics of 18F-AlF-RESCA-IL2. 
Previous SPECT and PET imaging studies have shown that IL2-derived tracers could 
detect T-cells in inflammatory and infectious diseases, as well as different tumor types (7-9, 23-
28). In a small clinical pilot study in only five patients with melanoma, 99mTc-IL2 SPECT could 
detect metastases (29). Currently, also other tracers targeting immune cells are being developed, 
such as targeting T-cells via CD8 specific tracers (30-33). Another method to detect immune cells 
is radiolabeling of immune checkpoint targeting monoclonal antibodies, with long half-life 
isotopes such as zirconium-89 (89Zr). Compared to these antibody-based tracers, radiolabeled IL2 
tracers have the advantage that with shorter half-lives, imaging can be performed shortly after 
tracer injection. Thus, in a fast, non-invasive manner, information about the presence and 
dynamics of immune cells can be gained. Our results indicate good in-vitro and in-vivo 




We developed two radiolabeled IL2 tracers for imaging of immune cells: 18F-AlF-
RESCA-IL2 and 68Ga-Ga-NODAGA-IL2. Production of the tracers was faster than the 
previously developed 18F-FB-IL2, potentially being an advantage for clinical use. 18F-AlF-
RESCA-IL2 showed highest practical production yield and highest in-vitro binding to activated 
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hPBMCs. Moreover, in-vivo studies showed high uptake of 18F-AlF-RESCA-IL2 in PBMCs 
xenografts and lymphoid tissues like spleen, bone marrow and lymph nodes. This supports the 
potential to use this tracer in future studies for detection of CD25-positive immune cells.  
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What are the in-vitro and in-vivo characteristics of two radiolabeled IL2 variants, 18F-AlF-
RESCA-IL2 and 68Ga-Ga-NODAGA-IL2, compared to 18F-FB-IL2?  
Pertinent Findings  
Production of the tracers is faster than previous developed 18F-FB-IL2. 18F-AlF-RESCA-
IL2 shows best in-vitro binding characteristics. In-vivo studies showed high 18F-AlF-RESCA-IL2 
uptake in PBMCs and lymphoid organs like spleen, bone marrow and lymph nodes .  
Implications For Patient Care 
Our results indicate the potential to use 18F-AlF-RESCA-IL2 in future molecular imaging 
studies for detection of CD25-positive immune cells. 
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FIGURES AND TABLES  
 
FIGURE 1. Structures of the radiolabeled interleukin-2 PET tracers.  
  




FIGURE 2. In-vitro binding assay in human PBMCs for 18F-FB-IL2, 18F-AlF-RESCA-IL2 and 
68Ga-Ga-NODAGA-IL2. Four independent experiments were performed for 18F-FB-IL2 and 18F-
AlF-RESCA-IL2, in triplicate, for 68Ga-Ga-NODAGA-IL2 two independent experiments were 
performed, in triplicate. A) Data expressed as percentage of cell-associated radioactivity per 








FIGURE 3. In-vitro stability studies in human serum for 18F-AlF-RESCA-IL2 and 68Ga-Ga-
NODAGA-IL2. Data expressed as percentage of intact tracer, after 60 and 120 min incubation. 
Data expressed as mean±SD.  
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FIGURE 4. Comparison of ex-vivo biodistribution in immunocompetent BALB/c mice 60 min 
p.i. between 18F-FB-IL2, 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 (n=6 per tracer). 
Uptake is expressed as percentage of injected dose (%ID/g). Data expressed as mean±SD; 
*P≤0.05, **P≤0.01. 
   




FIGURE 5. Representative PET images in immunodeficient SCID mice inoculated with 
activated PBMCs or Matrigel control in the right shoulder 15 min before tracer injection for A) 
18F-FB-IL2, B) 18F-AlF-RESCA-IL2 and C) 68Ga-Ga-NOGAGA-IL2. Clear lymph node uptake 
is depicted by red arrows. Upper panel transaxial view, lower panel coronal view. LN = lymph 








FIGURE 6. Ex-vivo uptake (%ID/g) of the three radiolabeled IL2 variants in mice inoculated 
with activated PBMCs or Matrigel control in the right shoulder 15 min before tracer injection. 
For blocking an excess of unlabeled IL2 was co-injected with radiolabeled IL2 (PBMC block). 
18F-FB-IL2: PBMC n=4, PBMC block  n=6, Matrigel control n=5; 18F-AlF-RESCA-IL2: PBMC 
n=5, PBMC block  n=6, Matrigel control n=6; 68Ga-Ga-NODAGA-IL2: PBMC n=5, PBMC 
block  n=6, Matrigel control n=5. Data expressed as mean±SD; *P≤0.05.  
 






Production Of 18F-AlF-RESCA-IL2  
First, aqueous 18F-fluoride was produced by irradiation of 18O-water with a cyclotron 
(Cyclon 18 Twin, IBA) via the 18O(p,n)18F nuclear reaction. The 18F-fluoride solution was passed 
through a QMA Sep-Pak Light anion exchange cartridge (Waters Chromatography Division, 
Millipore Corp, preconditioned with 3 mL metal free water) to recover the 18O-water. The QMA 
was then washed with 10 mL of metal free water and 10 mL of air. The 18F-fluoride was then 
eluted from the cartridge with 400 µL 0.9% sodium chloride (NaCl) (B. Braun). An 18F-AlF 
solution was freshly prepared by adding ~10 GBq 18F-fluoride in 400 μL 0.9% NaCl to 25 μL 
aluminum chloride (2 mM, 50 nmol) in 100 μL sodium acetate buffer 0.1 M, pH 4.5 (NaOAc, 
Sigma-Aldrich), and allowed to react at room temperature (RT) for 5 min. To the 18F-AlF 
solution, 40 μL of the restrained complexing agent-tetrafluorophenol ester ((±)-H3RESCA-TFP 
(50 nmol; NaOAc buffer, 0.1 M, pH 4.5; Leuven University, Belgium) was added. After 15 min 
of reaction at RT, the reaction mixture was diluted with 10 mL of water and transferred to an 
HLB cartridge (Waters Chromatography Division, Millipore Corp). 18F-AlF-RESCA-TFP was 
eluted from the cartridge with 0.6 mL ethanol and 0.7 mL sodium acetate (pH 8.5) into a vial 
containing 100 μL IL2 (17 nmol) in dimethyl sulfoxide (DMSO, Sigma-Aldrich). The 
conjugation occurred at 50oC for 15 min, after which the reaction was quenched with 25 μL 25% 
phosphoric acid (H3PO4) and 48 μL 10% sodium dodecyl sulfate (SDS, Sigma-Aldrich). The 
product was diluted in 10 mL of water for injections (WFI) and passed through a tC2 Sep-Pak 
cartridge (Waters Chromatography Division, Millipore Corp), which was preconditioned with 5 
mL ethanol (EtOH, Merck KGaA) followed by 5 mL of a solution of 5% EtOH containing 12 µL 
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of 2.5% H3PO4 and 10 mL of air). The cartridge was washed three times with 2 mL 50% aqueous 
EtOH containing 23 µL 0.25% H3PO4. 18F-AlF-RESCA-IL2 was eluted from the cartridge with 
0.8 mL 100% EtOH containing 5 µL 0.25% H3PO4 and 3.5 mL 5% glucose (Baxter) and 
collected in a vial containing 1.5 mL 5% glucose, 0.1% SDS and 0.5% human serum albumin 
(HSA, Sanquin) solution.  
Radiochemical identity and purity were assessed by instant thin-layer chromatography 
(iTLC), eluted in a solution of 75% aqueous acetonitrile (Rf 18F-AlF-RESCA-TFP=1 and Rf 18F-
AlF-RESCA-IL2=0) and by UPLC-ESI-HRMS using a Dionex Ultimate 3000 UPLC System 
(Thermo Fisher Scientific, Sunnyvale, USA) coupled in series to a UV detector and a radio-
activity detector (Berthold FlowStar LB513, Mx50–6 flow cell. The identity of the product was 
confirmed using native IL2 as reference material.  
 
Production Of 68Ga-Ga-NODAGA-IL2 
     Synthesis of NODAGA-IL2. To a solution of IL2 in DMSO (100 μL, 14 nmol), a 4-fold molar 
excess of a solution of NODAGA-NHS ester in DMSO (40 μL-55 nmol, Chematech) was added, 
followed by 5 μL N,N-diisopropylethylamine (pH 8.5). This mixture was incubated for 2 h at RT 
with slow stirring. The reaction was quenched with 25 μL 25% H3PO4 and 48 μL 10% SDS. The 
product was diluted in 10 mL of WFI and purified with a tC2 cartridge, as described above. The 
final product was eluted with 0.5 mL 100% EtOH, containing 5 µL 0.25% H3PO4, and 0.5 mL 
100% EtOH. The conjugate was kept at -800C until the day of radiolabeling.  
 
     Radiolabeling of 68Ga-Ga-NODAGA-IL2 (Method 1). 68Ga-Cl3 was eluted from a > 9 month old 
GMP 1110 MBq grade 68Ge/68Ga-generator was used (Eckert & Ziegler). 68Ga3+ was trapped in a 
PS-H+ cartridge (ABX)  and subsequently eluted from this cartridge with 1.5 mL 5M sodium 
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chloride (NaCl). To the defrosted solution of NODAGA-IL2, 100 μL  68Ga-Cl3 (20-100 MBq) 
and 300 μL 1.5M HEPES buffer (ABX) were added (pH between 3-5). After 15 min of 
conjugation at 50oC, the mixture was quenched with 25 μL 25% H3PO4 and 48 μL 10% SDS. The 
product was purified with a tC2 cartridge as described above. 68Ga-Ga-NODAGA-IL2 was eluted 
from the cartridge with 0.8 mL 100% EtOH, containing 5 µL 0.25% H3PO4, and 3.5 mL of 5% 
glucose and collected in a vial containing 1.5 mL of 5% glucose, 0.1% SDS and 0.5% HSA 
solution. The final product was analyzed by iTLC eluted with a 0.1M citric acid solution (Rf 
68Ga-Cl3=1 and Rf 68Ga-NODAGA-IL2=0) and by ultra-performance liquid tomography (UPLC).  
 
     Radiolabeling of 68Ga-Ga-NODAGA-IL2 (Method 2). 68Ga-Cl3 was eluted from a 68Ge/68Ga- 
generator with 6 mL 0.1M hydrochloric acid (HCl, Rotem Industries) into a vial containing 4 mL 
37% HCl to form a final HCl concentration of 4 M. The eluate was then passed through a PS-
HCO3- cartridge (Synthra®), preconditioned with successively 5 M HCl, 1 M HCl, WFI and 
again 5 M HCl). The cartridge was washed with 2 mL 4 M HCl  and dried under a strong flow of 
nitrogen to eliminate the excess 4 M HCl. [68Ga]Cl3 was subsequently eluted with 300 μL water 
(100-360 MBq) into an Eppendorf (metal free) containing 75 mg HEPES and 10 μL of 25% 
ammonia (Merck KGaA). This solution (pH 3-4) was added to the solution of NODAGA-IL2 and 
the pH was adjusted to 4-5 with 25% ammonia. After 15 min of conjugation at 50oC, the mixture 
was quenched with 25 μL H3PO4 25% and 48 μL 10% SDS. The product was purified, 
formulated and analyzed as mentioned above.  
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SUPPLEMENTARY FIGURES AND TABLES 
 
SUPPLEMENTARY FIGURE 1. FACS analysis for in vitro experiments. Expression of 
CD25+ was determined in lymphocyte, CD3 positive, population of activated (A) and non-
activated (NA) hPBMCs. Data expressed as mean±SD; *P≤0.05, **P≤0.01. 
 
SUPPLEMENTARY FIGURE 2. Stability in vivo determined by TCA precipitation assay in 
plasma samples of immunocompetent BALB/c mice collected 15, 60 and 90 min after tracer 
injection (n=6 per time point for each tracer). Data expressed as mean±SD.   
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Supplementary TABLE 1 Ex vivo biodistribution of three radiolabeled IL2 tracers. 15, 60 and 90 min post-injection in BALB/c mice.  
Organs  18F-FB-IL2 (%ID/g) 18F-AlF-RESCA-IL2 (%ID/g) 68Ga-Ga-NODAGA-IL2 (%ID/g) 
15 min 60 min 90 min 15 min 60 min 90 min 15 min 60 min 90 min 
Whole blood 7.7 ± 2.1 3.1 ± 2.0 2.3 ± 1.4 7.9 ± 3.7 1.8 ± 0.4 1.2 ± 0.3 3.9 ± 1.2 0.9 ± 0.3 0.8 ± 0.4 
Plasma 10.0 ± 1.8 4.0 ± 2.6 2.9 ± 1.5 6.0 ± 2.2 2.1 ± 0.7 1.4 ± 0.3 6.7 ± 2.2 1.2 ± 0.5 1.3 ± 0.9 
Heart 6.5 ± 2.5 3.1 ± 2.1 2.8 ± 2.2 6.8 ± 5.3 2.9 ± 1.9 3.1 ± 2.8 2.1 ± 0.7 0.8 ± 0.1 0.8 ± 0.3 
Lung 13.7 ± 5.2 6.9 ± 4.8 8.8 ± 6.7 11.8 ± 9.5 8.0 ± 8.7 5.3 ± 5.8 5.6 ± 3.4 2.9 ± 1.9 2.7 ± 1.1 
Salivary gland 1.5 ± 0.5 1.1 ± 0.7 0.9 ± 0.3 1.7 ± 0.8 0.9 ± 0.1 0.7 ± 0.2 1.8 ± 0.4 1.1 ± 0.3 1.1 ± 0.4 
Thymus 2.1 ± 0.6 1.8 ± 1.6 1.4 ± 1.0 2.1 ± 0.7 1.6 ± 0.5 1.8 ± 1.6 2.0 ± 0.9 1.1 ± 0.4 1.3 ± 0.5 
Liver 25.9 ± 8.2 9.6 ± 7.8 4.2 ± 2.9 34.8 ± 10.6 31.3 ± 6.3 25.9 ± 8.7 22.0 ± 3.8 22.9 ± 4.3 26.6 ± 4.7 
Kidney 18.4 ± 5.9 18.9 ± 9.4 14.4 ± 4.3 41.0 ± 11.7 49.6 ± 22.2 39.1 ± 14.1 114.9 ± 21.0 162.8 ± 18.9 197.2 ± 25.6 
Urine 33.7 ± 13.3 111.6 ± 62.3 432.0 ± 325.6 4.8 ± 3.1 38.7 ± 12.0 71.0 ± 20.9 16.7 ± 22.7 15.8 ± 9.4 20.1 ± 8.5 
Bladder 5.9 ± 3.0 27.2 ± 23.9 126.9 ± 102.5 4.0 ± 3.6 10.3 ± 5.3 14.4 ± 6.4 7.8 ± 6.3 2.7 ± 1.2 2.2 ± 1.4 
Stomach 1.2 ± 0.3 1.1 ± 0.7 1.2 ± 1.0 1.6± 0.3 1.1 ± 0.4 1.8 ± 1.5 1.5 ± 0.3 0.8 ± 0.2 0.8 ± 0.3 
Pancreas 1.4 ± 0.5 1.4 ± 0.9 1.4  ± 1.5 1.3 ± 0.5 1.0 ± 0.9 0.8  ± 0.6 0.9 ± 0.2 0.5 ± 0.1 0.8 ± 0.5 
Spleen 22.4 ± 11.8 13.9 ± 10.0 9.2  ± 6.3 41.0 ± 30.9 43.6 ± 26.7 33.6 ± 31.7 19.8 ± 3.2 19.8 ± 3.5 22.8 ± 4.4 
Small intestine  1.8 ± 0.6 3.2 ± 2.4 1.7  ± 0.8 4.5 ± 1.5 4.3 ± 2.9 4.7 ± 4.3 1.6 ± 0.4 0.8 ± 0.1 0.9 ± 0.3 
Colon 1.3 ± 0.4 1.1 ± 0.7 1.8  ± 2.9 1.4 ± 0.4 1.0 ± 0.5 0.9 ± 0.5 2.0 ± 0.5 1.1 ± 0.3 1.4 ± 0.7 
Lymph node (axillary) 1.9 ± 1.6 3.0 ± 2.5 0.5  ± 0.4 4.6 ± 2.9 3.0 ± 2.3 6.6 ± 6.3 3.7 ± 4.0 2.4 ± 2.6 3.5 ± 3.1 
Lymph node (mesenteric) 1.6 ± 0.4 1.8 ± 0.9 3.5  ± 5.0 2.2 ± 0.6 2.0 ± 1.1 1.9 ± 1.1 3.5 ± 1.2 3.3 ± 1.6 7.0 ± 7.7 
Muscle  0.6 ± 0.1 0.5 ± 0.2 0.5  ± 0.2 0.5 ± 0.2 0.8 ± 1.3 0.3 ± 0.1 0.5 ± 0.1 0.2 ± 0.1 0.3 ± 0.3 
Skin 0.7 ± 0.1 1.0 ± 0.7 2.6  ± 2.3 1.0 ± 0.5 0.7 ± 0.4 1.5 ± 1.9 1.0 ± 0.3 0.9 ± 0.2 0.8 ± 0.3 
Brain  0.3 ± 0.1 0.2 ± 0.1 0.2  ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 
Bone  2.1 ± 1.0 0.7 ± 0.4 0.7  ± 0.2 3.3 ± 1.1 3.9 ± 1.2 4.9 ± 1.4 1.1 ± 0.3 0.7 ± 0.3 0.9 ± 0.5 
Bone marrow  38.7 ± 19.7 8.8 ± 8.6 14.3  ± 24.8 26.8 ± 16.5 26.9± 12.4 19.2 ± 7.3 11.7 ± 1.3 9.3 ± 2.7 12.3 ± 3.7 
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Supplementary TABLE 2 Ex vivo biodistribution of three radiolabeled IL2 tracers in immunodeficient SCID mice, inoculated with human 
activated PBMCs, 15 min before tracer injection. After tracer injection a 60 min dynamic PET scan was made, followed by ex vivo biodistribution 
studies. Activity in each organ was measured and the percentage of the injected dose (%ID/g) was calculated.  
Organs  18F-FB-IL2 (%ID/g) 18F-AlF-RESCA-IL2 (%ID/g) 68Ga-Ga-NODAGA-IL2 (%ID/g) 
PBMC  PBMC block Matrigel  PBMC PBMC block Matrigel PBMC PBMC block Matrigel 
Whole blood 6.4 ± 2.9 3.8 ± 2,6 3.6 ± 1.4 1.2 ± 0.6 1.1 ± 0.8 1.5 ± 0.9 2.3 ± 0.6 2.0 ± 0.7 2.6 ± 1.8 
Plasma 7.8 ± 2.8 3.2 ± 2,0 3.7 ± 0.7 1.7 ± 1.1 0.6 ± 0.9 1.4 ± 0.5 3.2 ± 0.9 2.9 ± 1.4 4.5 ± 1.9 
Heart 8.9 ± 4.7 8.2 ± 6,4 6.6 ± 6.4 0.9 ± 0.3 8.7 ± 18.7  0.9 ± 0.3 1.2 ± 0.3 1.3 ± 0.6 1.3 ± 0.4 
Lung 13.6 ± 5.5  23.0 ± 19.9 8.3 ± 6.8 2.8 ± 1.0  5.7 ± 3.2 3.2 ± 1.9 2.8 ± 1.3 4.9 ± 4.8 2.8 ± 1.4 
Salivary gland 2.1 ± 0.7 1.5 ± 1.0 1.4 ± 0.6  0.6 ± 0.3 0.6 ± 0.2 0.6 ± 0.3 1.1 ± 0.2 1.2 ± 0.6 1.1 ± 0.2 
Thymus 5.9 ± 3.6  4.2 ± 1.6  2.9 ± 1.1 1.9 ± 1.3 2.4 ± 1.7 2.0 ± 1.7 1.7 ± 0.8 1.7 ± 0.6 1.2 ± 0.9 
Liver 23.1 ± 14.2 16.4 ± 12.5 14.3 ± 7.3 32.9 ± 11.7 39.0 ± 16.9  37.7 ± 17.3 30.5 ± 16.2 29.0 ± 13.5 36.5 ± 13.1 
Kidney 29.9 ± 9.2 15.9 ± 14.1  17.7 ± 4.6 42.7± 42.9 32.2 ± 26.6 42.6 ± 40.4 40.2 ± 44.9 38.9 ± 25.0 52.2 ± 13.7 
Urine 499.3 ± 383.7 253.7 ± 122.7 231.0 ± 160.7 16.8 ± 18.0 17.4 ± 9.3 24.1 ± 26.4 7.5 ± 10.1 17.1 ± 17.4 11.6 ± 4.4 
Bladder 39.7 ± 22.9 52.1 ± 21.9 134.1 ± 136.5 7.0 ± 5.5  3.9 ± 3.9 8.9 ± 8.3 3.0 ± 3.3 3.2 ± 1.5 3.6 ± 2.6 
Stomach 2.3 ± 1.1 1.4 ± 0.5 1.1 ± 0.4 0.6 ± 0.2  0.8 ± 0.3 0.6 ± 0.2 0.8 ± 0.2 0.7 ± 0.4 6.8 ± 10.2 
Pancreas 2.2 ± 0.7 2.0 ± 0.5 1.4 ± 0.5 0.6 ± 0.2 0.5 ± 0.3 0.5 ± 0.2 0.8 ± 0.3 0.6 ± 0.2 1.0 ± 0.5 
Spleen 18.6 ± 13.4 20.9 ± 15.5 10.5 ± 5.9  12.3 ± 7.0 14.3 ± 6.6 15.2 ± 7.5 17.0 ± 12.0 18.8 ± 8.1 11.4 ± 0.4 
Small intestine  4.7 ± 0.9 2.5 ± 1.2 3.3 ± 1.6 2.1 ± 1.2 2.1 ± 1.1 2.8 ± 1.5 1.1 ± 0.2 0.7 ± 0.3 1.6 ± 0.7 
Colon 2.2 ± 0.9 1.9 ± 1.0 1.3 ± 0.3 0.9 ± 0.4 0.7 ± 0.3 1.0 ± 0.6 1.1 ± 0.2 0.6 ± 0.1 1.2 ± 0.6 
Lymph node (axillary) 4.4 ± 4.4 1.6 ± 0.9 1.9 ± 1.9  6.6 ± 11.3  1.0 ± 1.1 1.0 ± 0.9 1.9 ± 1.6 4.4 ± 5.7 1.2 ± 1.3 
Lymph node (mesenteric) 2.6 ± 1.1 2.8 ± 2.0 2.9 ± 1.4  3.2 ± 5.9 0.7 ± 0.4 1.3 ± 0.7 1.1 ± 0.4 0.8 ± 0.6 0.8 ± 0.3 
Muscle  0.9 ± 0.3 0.6 ± 0.2 0.5 ± 0.1 0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.1 0.5 ± 0.3 0.4 ± 0.1 0.4 ± 0.2 
Skin 2.4 ± 1.6 1.0 ± 0.4 0.9 ± 0.7  0.6 ± 0.2 0.6 ± 0.3 0.6 ± 0.3 1.0 ± 0.4 0.7 ± 0.2 1.3 ± 0.4 
Brain  0.3 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 
Brown adipose tissue 1.9 ± 0.8  1.1 ± 0.6 0.8 ± 0.3 0.5 ± 0.3 0.9 ± 0.7 0.3 ± 0.1 0.5 ± 0.2 0.6 ± 0.3 0.7 ± 0.3 
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Bone  1.7 ± 0.7 1.1 ± 0.5  0.7 ± 0.2 4.3 ± 2.6  3.2 ± 1.2 3.9 ± 2.6 1.7 ± 1.0 1.0 ± 0.6 1.9 ± 0.8 
Bone marrow  15.7 ± 5.9 11.2 ± 6.4  10.3 ± 5.7 17.2 ± 11.3 17.6 ± 16.5 12.1 ± 9.8 7.7 ± 4.8 14.3 ± 11.9 9.8 ± 6.7 
PBMCs 2.0 ± 0.5 1.2 ± 0.4  0.9 ± 0.3 2.0 ± 1.4 0.7 ± 0.3 0.5 ± 0.4 1.1 ± 0.5 0.8 ± 0.4 0.5 ± 0.2 
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